VANCOUVER, BC, Sept. 19, 2023 /PRNewswire/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies congratulates the Multidisciplinary Association of Psychedelics Studies (“MAPS”) on the results of their phase 3 results. These findings were published last…


Previous articleNuminus Takes Actions to Accelerate its Path to Profitability by Focusing on Positive Cash Flow Generating Operations
Next articlePsychedelic Bulletin #145: MAPS’ Second Phase 3 Study Published; EMA’s New Draft Guideline on Depression Drug Dev Includes Psychedelics; California’s Decrim. Bill Goes to Governor